Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details under a deferred bonus plan. The share price at the time of the transaction was 1345 pence per Ordinary share and $41.83 per ADR.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details routine increases in notional interests in Ordinary shares and ADRs for specific executives following the re-investment of dividends paid on October 6, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It notes that notional dividends accrued will be paid out in proportion to the percentage of deferred annual bonus holdings vesting after a three-year measurement period. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: October 7, 2011.
- Share Price: 1345 pence per Ordinary share; $41.83 per ADR.
- Participants: Mr A P Witty, Mr S M Bicknell, Mrs D P Connelly, Mr D S Redfern, Dr M M Slaoui, Ms C Thomas, Mr D E Troy, and Dr P J T Vallance.
- Transaction Type: Acquisition of shares/ADRs via dividend re-investment (personal contribution) and matching elements (Company contribution) under the 2009 Deferred Annual Bonus Plan.
- Signatory: Victoria Whyte, Company Secretary.